Loading...
•
Sep 30, 2022
Royalty Pharma Q3 2022 Earnings Report
Royalty Pharma's financial results for Q3 2022 were reported, demonstrating growth in operating cash flow and adjusted cash receipts.
Key Takeaways
Royalty Pharma reported a 15% increase in net cash provided by operating activities, reaching $539 million, and a 2% increase in Adjusted Cash Receipts, totaling $597 million. The company announced transactions of up to $3.0 billion year-to-date, including $1.7 billion in upfront payments. Royalty Pharma increased its full-year 2022 guidance for Adjusted Cash Receipts to $2,750 to $2,800 million.
Net cash provided by operating activities (GAAP) increased 15% to $539 million.
Adjusted Cash Receipts increased 2% to $597 million, driven by strong portfolio performance and the acquisition of royalties on Trelegy.
Adjusted EBITDA grew 3% to $548 million.
Adjusted Cash Flow increased 26% to $441 million.
Revenue by Segment
Forward Guidance
Royalty Pharma anticipates full-year 2022 Adjusted Cash Receipts to be between $2,750 million and $2,800 million. The guidance reflects an estimated foreign exchange impact of approximately -3% to -4% for full-year 2022 year/year Adjusted Cash Receipts growth, assuming current exchange rates prevail for the balance of 2022.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...